Furthermore, the anti-PD-1 antibody has been reported to enhance the efficacy of lenvatinib by altering the immune system, and lenvatinib can enhance the anti-tumor efficacy of anti-PD-1 immunotherapy [37]. Here, PDCD1 is linked to neoplasm.